Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BlueJays9293on Aug 21, 2024 11:44am
116 Views
Post# 36189910

RE:Wolf guarding the sheep: a good thing...?

RE:Wolf guarding the sheep: a good thing...?The "buyer" Carlyle Group, just ganked, their "friend" Baxter, to the tune of Over two hundred million dollars. 

Carlyle Group knew Baxter was desperate for cash and CG exploited that to the MAX.

Your narrative is pure fantasy land big boy.

Don't believe me?

Here's what the Wall Street Journal said in early July,

Carlyle in Advanced Talks to Acquire Baxter’s Vantive

Deal would value the Baxter spinoff at more than $4 billion


"Private-equity firm Carlyle Group CG -1.06%decrease; red down pointing triangle is in exclusive talks to acquire medical-device maker Baxter’s kidney-care spinoff Vantive for more than $4 billion."


<< Previous
Bullboard Posts
Next >>